Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Glade Roper

Vascular & Interventional Radiology Visalia, CA Medical Doctor

NPI 1033385810 CMS profile 506705

1700 S Court St Ste A, Ste A, Visalia, CA 93277

Open in the dashboard

General payments

$67,683

225 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Glade Roper of Visalia, CA is reported in the CMS Open Payments database as having received $67,683 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,652 64
2024 General $17,651 54
2023 General $12,581 63
2022 General $7,710 39
2020 General $17 1
2019 General $72 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Glade Roper
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Glade Roper were reported at $29,652. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Glade Roper Vascular & Interventional Radiology median Middle half National median
2019 $72 $422 $125–$1,555 $163
2020 $17 $200 $68–$652 $114
2021 $0 $280 $99–$866 $132
2022 $7,710 $433 $137–$1,497 $149
2023 $12,581 $506 $152–$2,019 $160
2024 $17,651 $556 $175–$1,930 $164
2025 $29,652 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $51,039 161 payments
  2. Spinal Simplicity, LLC $7,336 8 payments
  3. Nalu Medical, Inc. $4,162 18 payments
  4. AngioDynamics, Inc. $2,789 3 payments
  5. Merit Medical Systems Inc $1,293 4 payments
  6. Vertos Medical, Inc. $260 4 payments
  7. Relievant Medsystems, Inc. $226 7 payments
  8. Boston Scientific Corporation $187 2 payments
  9. Bard Peripheral Vascular, Inc. $54 2 payments
  10. Amgen Inc. $53 2 payments
  11. Other $283 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $27,243 19 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,780 11 payments
  3. Travel and Lodging $10,093 36 payments
  4. Food and Beverage $5,028 153 payments
  5. Long term medical supply or device loan $2,789 3 payments
  6. Education $2,000 2 payments
  7. Compensation for serving as faculty or as a speaker for a medical education program $750 1 payment
Products named General payments · program years 2019–2025
  1. KYPHON EXPRESS II KYPHOPAK TRAY $26,207 61 payments
  2. OSTEOCOOL RF ABLATION SYSTEM $7,944 30 payments
  3. HA MINUTEMAN G3-R $5,524 6 payments
  4. Nalu Neurostimulation System $4,162 18 payments
  5. INTELLIS ADAPTIVESTIM $2,331 27 payments
  6. VenaCure 1470 Pro Et $1,829 2 payments
  7. LIBERTY SI $1,813 2 payments
  8. VenaCure 1470 Pro Id $960 1 payment
  9. STAR Tumor Ablation System $943 3 payments
  10. Ascenda $750 1 payment
  11. Other $2,541 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

196

Median for Diagnostic Radiology: 24

Drug cost

$948

Median for Diagnostic Radiology: $190

Branded share of claims

22.4%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 57 $264
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 22 $246
Meloxicam Generic 68 $121
Tizanidine Hcl Generic 16 $112
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 22 $107
Methylprednisolone Generic 11 $98

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 255 billing codes

Paid by Medicare

$760,585

Of which drugs: $4,940

Medicare patients

2,868

Average age 74

Services billed

56,609

1,517 women, 1,351 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 46%
Ischemic heart disease 40%
Chronic kidney disease 36%
Heart failure 31%
Depression 29%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadoterate meglumine, 0.1 ml A9575 Office 226 42,302 $3,934
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 93 9,061 $911
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 126 $94

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record